For the year ending 2025-12-31, NVNO had $1,311K increase in cash & cash equivalents over the period. -$15,573K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -19,472 |
| Stock-based compensation | 3,420 |
| Depreciation and amortization | 136 |
| Amortization of right-of-use assets | 353 |
| Unrealized loss from investments | -391 |
| Prepaid expenses and other current assets | 33 |
| Accounts payable, accrued expenses and other current liabilities | 1 |
| Operating lease liabilities | -364 |
| Net cash used in operating activities | -15,568 |
| Maturities of investments | 61,879 |
| Purchase of investments | 46,018 |
| Purchases of property and equipment | 5 |
| Net cash provided by investing activities | 15,856 |
| Proceeds from sale of common stock in at-the-market offering, net of fees | 782 |
| Proceeds from exercise of warrants | 241 |
| Net cash provided by financing activities | 1,023 |
| Net increase (decrease) in cash and cash equivalents | 1,311 |
| Cash and cash equivalents, beginning of year | 1,754 |
| Cash and cash equivalents, end of year | 3,065 |
enVVeno Medical Corp (NVNO)
enVVeno Medical Corp (NVNO)